PuSH - Publikationsserver des Helmholtz Zentrums München: Deoxyguanosine kinase deficiency: Natural history and liver transplant outcome.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Manzoni, E.* ; Carli, S.* ; Gaignard, P.* ; Schlieben, L.D. ; Hirano, M.* ; Ronchi, D.* ; Gonzales, E.* ; Shimura, M.* ; Murayama, K.* ; Okazaki, Y.* ; Barić, I.* ; Petkovic Ramadža, D.* ; Karall, D.* ; Mayr, J.* ; Martinelli, D.* ; La Morgia, C.* ; Primiano, G.* ; Santer, R.* ; Servidei, S.* ; Bris, C.* ; Cano, A.* ; Furlan, F.* ; Gasperini, S.* ; Laborde, N.* ; Lamperti, C.* ; Lenz, D.* ; Mancuso, M.* ; Montano, V.* ; Menni, F.* ; Musumeci, O.* ; Nesbitt, V.* ; Procopio, E.* ; Rouzier, C.* ; Staufner, C.* ; Taanman, J.W.* ; Tal, G.* ; Ticci, C.* ; Cordelli, D.M.* ; Carelli, V.* ; Procaccio, V.* ; Prokisch, H. ; Garone, C.*

Deoxyguanosine kinase deficiency: Natural history and liver transplant outcome.

Brain Commun. 6:fcae160 (2024)

Verlagsversion

DOI

PMC

	Open Access Gold

Abstract
Metriken
Zusatzinfos

Autosomal recessive pathogenetic variants in the DGUOK gene cause deficiency of deoxyguanosine kinase activity and mitochondrial deoxynucleotides pool imbalance, consequently, leading to quantitative and/or qualitative impairment of mitochondrial DNA synthesis. Typically, patients present early-onset liver failure with or without neurological involvement and a clinical course rapidly progressing to death. This is an international multicentre study aiming to provide a retrospective natural history of deoxyguanosine kinase deficient patients. A systematic literature review from January 2001 to June 2023 was conducted. Physicians of research centres or clinicians all around the world caring for previously reported patients were contacted to provide followup information or additional clinical, biochemical, histological/histochemical, and molecular genetics data for unreported cases with a confirmed molecular diagnosis of deoxyguanosine kinase deficiency. A cohort of 202 genetically confirmed patients, 36 unreported, and 166 from a systematic literature review, were analyzed. Patients had a neonatal onset (≤ 1 month) in 55.7% of cases, infantile (>1 month and ≤ 1 year) in 32.3%, pediatric (>1 year and ≤18 years) in 2.5% and adult (>18 years) in 9.5%. Kaplan-Meier analysis showed statistically different survival rates (P < 0.0001) among the four age groups with the highest mortality for neonatal onset. Based on the clinical phenotype, we defined four different clinical subtypes: hepatocerebral (58.8%), isolated hepatopathy (21.9%), hepatomyoencephalopathy (9.6%), and isolated myopathy (9.6%). Muscle involvement was predominant in adult-onset cases whereas liver dysfunction causes morbidity and mortality in early-onset patients with a median survival of less than 1 year. No genotype-phenotype correlation was identified. Liver transplant significantly modified the survival rate in 26 treated patients when compared with untreated. Only six patients had additional mild neurological signs after liver transplant. In conclusion, deoxyguanosine kinase deficiency is a disease spectrum with a prevalent liver and brain tissue specificity in neonatal and infantile-onset patients and muscle tissue specificity in adult-onset cases. Our study provides clinical, molecular genetics and biochemical data for early diagnosis, clinical trial planning and immediate intervention with liver transplant and/or nucleoside supplementation.

Impact Factor

Scopus SNIP

Altmetric

4.100

0.000